MedTrace Logo

Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty

NCT03808155 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2025-09-03

No results posted yet for this study

Summary

Various studies have shown that the risk of suffering a urinary retention after knee or hip prosthesis surgery is 10-80%. The aim of the study is to reduce this riks. For this purpose, it is investigated whether a previously known drug (tamsulosin) which is used in bladder emptying disorders, can achieve a reduction in urinary retention after surgery. After the patients agree to participate in the study, they are examined in our urological clinic. Uroflowmetry is performed with sonographic residual volume measurement and prostate volume measurement. Furthermore, a standardized Voiding questionaire (IPSS) is completed. This study is conducted as a double-blind study using a placebo control group. The drug / placebo is taken once a day, five days before and two days after surgery. Subsequently, it is observed whether it comes to a urinary retention or not. After the operation, no further urological checks are planned or needed.

Conditions

  • Urinary Retention Postoperative
  • Arthropathy of Knee
  • Arthropathy of Hip

Interventions

DRUG

Tamsulosin

The drug ist taken once a day per os five days prior to the operation and two days after the operation.

DRUG

Placebo Oral Tablet

The placebo ist taken once a day per os five days prior to the operation and two days after the operation.

Sponsors & Collaborators

  • Kantonsspital Graubünden

    lead OTHER

Principal Investigators

  • Räto T. Strebel, PD Dr. med. · Kantonsspital Graubünden

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2024-10-22
Completion
2025-03-04

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808155 on ClinicalTrials.gov